• Median Technologies highlighted commercial launch preparations for eyonis LCS, an AI imaging software device for lung cancer screening, following FDA 510(k) clearance.
• U.S. rollout plan centers on phased regional expansion, build-out of direct enterprise sales, non-exclusive distribution partnerships, with Tempus named as first distributor.
• Manufacturer performance data cited NPV of 99.9% on a U.S. cohort of 2,163 cases, with sensitivity of 93.3% and specificity of 92.4% versus 80.3% and 76.4% for radiologists.
• Reimbursement framework referenced CPT III codes 0721T and 0722T, with hospital outpatient payment shown at $650 for tissue characterization, alongside $107 for LDCT under code 71271.
• FY2025 revenue shown at EUR 23.4 million, with backlog of EUR 76.6 million as of Dec. 31, 2025; refinancing completed up to EUR 61.4 million, including EUR 37.5 million EIB financing with EUR 18.5 million undrawn.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.